Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHKA | P35790 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223438 | 1.00 | KDM4E (0.58) | KDM4EHDAC1MEN1KMT2ACCR5 | |
| SCHEMBL17313634 | 1.00 | KDM4E (0.58) | KDM4EHDAC1MEN1KMT2ACCR5 | |
| SCHEMBL4699032 | 0.88 | KDM4E (0.56) | KDM4EHDAC1LMNALTA4HCHRM4 | |
| SCHEMBL28169444 | 0.86 | HDAC1 (0.50) | KDM4EHDAC1LTA4HCHRM4 | |
| SCHEMBL4578100 | 0.85 | HDAC1 (0.58) | HDAC1LTA4HCHRM4 | |
| SCHEMBL4578108 | 0.85 | HDAC1 (0.58) | HDAC1LTA4HCHRM4 | |
| SCHEMBL15860138 | 0.85 | HDAC1 (0.58) | HDAC1LTA4HCHRM4 | |
| SCHEMBL8230948 | 0.84 | HDAC1 (0.54) | KDM4EHDAC1MEN1KMT2ALTA4H | |
| SCHEMBL20257082 | 0.83 | KDM4E (0.62) | KDM4EMEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL5179140 | 0.82 | HDAC1 (0.60) | HDAC1LTA4HCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | KDM4E 659/4885HDAC1 471/4885MEN1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.